SCHEMBL31696629

SCHEMBL31696629

Cn1nc(C(F)(F)F)nc1C(=O)N[C@H]1CCn2nc(-c3ccnc(C(C)(F)F)c3)cc21

nearest known ligand 0.37

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KCNT1 Q5JUK3 3/20 0.37
RAF1 P04049 10/20 0.35
BRAF P15056 10/20 0.35
KCNQ1 P51787 1/20 0.35
KCNH2 Q12809 1/20 0.35
CACNA1C Q13936 1/20 0.35
SCN5A Q14524 1/20 0.35
KCNMB1 Q16558 1/20 0.35
KCNT2 Q6UVM3 1/20 0.35
USP30 Q70CQ3 1/20 0.35
RIPK1 Q13546 3/20 0.34
PDE4B Q07343 2/20 0.34
PDE4D Q08499 2/20 0.34
PDE4A P27815 1/20 0.34
PDE4C Q08493 1/20 0.34
MAP3K12 Q12852 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31696380 0.95 KCNT1 (0.40) KCNT1RAF1KCNQ1KCNH2CACNA1C
SCHEMBL31696566 0.84 RAF1 (0.41) RAF1BRAFPDE4BPDE4DPDE4A
SCHEMBL31696462 0.84 KCNT1 (0.38) KCNT1RAF1KCNQ1KCNH2CACNA1C
SCHEMBL31696519 0.84 KCNT1 (0.40) KCNT1RAF1BRAFKCNQ1KCNH2
SCHEMBL31696390 0.84 KCNT1 (0.38) KCNT1RAF1KCNQ1KCNH2CACNA1C
SCHEMBL31696571 0.80 KCNT1 (0.51) KCNT1KCNQ1KCNH2CACNA1CSCN5A
SCHEMBL31696485 0.80 KCNT1 (0.51) KCNT1KCNQ1KCNH2CACNA1CSCN5A
SCHEMBL31696441 0.80 KCNT1 (0.51) KCNT1KCNQ1KCNH2CACNA1CSCN5A
SCHEMBL31696512 0.80 RIPK1 (0.34) KCNT1RAF1BRAFUSP30RIPK1
SCHEMBL31696554 0.79 RIPK1 (0.35) RIPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12630533-B2 Heterocyclic compounds useful as KCNT1 inhibitors ACTIO BIOSCIENCES, INC. (US) 2026-05-19 US disclosed
US-20250313548-A1 HETEROCYCLIC COMPOUNDS USEFUL AS KCNT1 INHIBITORS ACTIO BIOSCIENCES, INC. 2025-10-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250313548-A1 HETEROCYCLIC COMPOUNDS USEFUL AS KCNT1 INHIBITORS KCNT1, KCNT2, KCNN3 KCNT1 1/4885RAF1 1052/4885BRAF 1911/4885
US-12630533-B2 Heterocyclic compounds useful as KCNT1 inhibitors KCNT1, KCNT2, KCNJ2 KCNT1 1/4885RAF1 814/4885BRAF 2042/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.